These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27120993)

  • 1. Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort.
    Ruiz-Genao D; Perez-Zafrilla B; Lopez-Estebaranz JL; Belinchón-Romero I; Carrascosa JM; Ferrán M; Vanaclocha F; Herrera-Ceballos E; García-Doval I;
    Br J Dermatol; 2017 Mar; 176(3):797-799. PubMed ID: 27120993
    [No Abstract]   [Full Text] [Related]  

  • 2. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab.
    Čarija A; Ivić I; Marasović-Krstulović D; Puizina-Ivić N
    Rheumatology (Oxford); 2015 Nov; 54(11):2114-6. PubMed ID: 26242857
    [No Abstract]   [Full Text] [Related]  

  • 3. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
    Belinchón I; Ramos JM; Carretero G; Ferrándiz C; Rivera R; Daudén E; De la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Sánchez-Carazo JL; López-Estebaranz JL; Alsina M; Ferrán M; Torrado R; Carrascosa JM; Llamas-Velasco M; Ortiz PL; García-Doval I; Descalzo MA;
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1700-1708. PubMed ID: 28485816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry.
    Medina C; Carretero G; Ferrandiz C; Dauden E; Vanaclocha F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Carrascosa JM; Torrado R; Argila D; Rivera R; Jiménez-Puya R; García-Doval I;
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):858-64. PubMed ID: 25185962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients.
    Jones BB; Millsop JW; Walsh JA; Krueger GG; Callis Duffin K
    Br J Dermatol; 2015 Jul; 173(1):272-4. PubMed ID: 25557081
    [No Abstract]   [Full Text] [Related]  

  • 6. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.
    de Souza A; Ali-Shaw T; Reddy SM; Fiorentino D; Strober BE
    Br J Dermatol; 2013 Jan; 168(1):210-2. PubMed ID: 23278559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biologics. New drugs, new adverse reactions].
    Prinz JC
    Hautarzt; 2010 Aug; 61(8):668-75. PubMed ID: 20585746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries.
    Kojanova M; Fialova J; Cetkovska P; Gkalpakiotis S; Jircikova J; Dolezal T; Arenberger P;
    Int J Dermatol; 2017 Apr; 56(4):428-434. PubMed ID: 28181669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
    Suruki RY; Desai RJ; Davis KJ; Berlin JA; Gagne JJ
    Rheumatology (Oxford); 2022 Aug; 61(8):e236-e237. PubMed ID: 35333307
    [No Abstract]   [Full Text] [Related]  

  • 11. Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
    Ouyang F
    Rheumatology (Oxford); 2022 Oct; 61(10):e320. PubMed ID: 35686859
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply.
    Pina Vegas L; Claudepierre P; Sbidian E
    Rheumatology (Oxford); 2022 Aug; 61(8):e238-e239. PubMed ID: 35333297
    [No Abstract]   [Full Text] [Related]  

  • 13. Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply.
    Pina Vegas L; Claudepierre P; Sbidian E
    Rheumatology (Oxford); 2022 Oct; 61(10):e321-e322. PubMed ID: 35686890
    [No Abstract]   [Full Text] [Related]  

  • 14. Paradoxical Arthritis Due to Ixekizumab in a Patient With Plaque Psoriasis.
    Vidal D; Ros S; Reina D
    Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):255-256. PubMed ID: 29861037
    [No Abstract]   [Full Text] [Related]  

  • 15. Injection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis.
    Henderson Berg MH; Carrasco D
    J Drugs Dermatol; 2017 Jul; 16(7):695-698. PubMed ID: 28697222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region.
    Al Hammadi A; Al-Sheikh A; Ammoury A; Ghosn S; Gisondi P; Hamadah I; Kibbi AG; Shirazy K
    J Dermatolog Treat; 2017 Mar; 28(2):129-135. PubMed ID: 27196814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Side effects of biologic therapies in psoriasis].
    Altenburg A; Augustin M; Zouboulis CC
    Hautarzt; 2018 Apr; 69(4):290-297. PubMed ID: 29568996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of systemic treatments for psoriasis in elderly patients.
    Piaserico S; Conti A; Lo Console F; De Simone C; Prestinari F; Mazzotta A; Gualdi G; Guarneri C; Borsari S; Cassano N
    Acta Derm Venereol; 2014 May; 94(3):293-7. PubMed ID: 24158307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
    Carretero G; Ferrandiz C; Dauden E; Vanaclocha Sebastián F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina-Gibert M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Carazo C; Rivera R; Jiménez-Puya R; García-Doval I;
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):156-63. PubMed ID: 24684267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report].
    Rivera R; García-Doval I; Carretero G; Daudén E; Sánchez-Carazo J; Ferrándiz C; Herrera E; Alsina M; Ferrán M; López-Estebaranz JL; Gómez F; Herranz JM; Carrascosa JM; Vanaclocha F;
    Actas Dermosifiliogr; 2011 Mar; 102(2):132-41. PubMed ID: 21377137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.